Wednesday, 11 December 2019
The Authority would like to advise all its stakeholders that with effect from the 25th of June 2019, the following online reporting platforms will be available for all our stakeholders and will be accessible on the MCAZ website:
Please download the Circular for more information
The Authority hereby notifies relevant stakeholders on a potential risk of neural defects which has been reported in infants born to women who were taking Dolutegravir at the time of conception. The safety issue was identified from a preliminary unscheduled analysis of ongoing observational study in Botswana.
Please download the circular for more information.
The Authority wishes to notify healthcare professionals of reinforcement of safety information about serios low blood sugar levels and mental health side effects associated with fluoroquinolone antibiotics.
Please download the circular for more information.
The Authority has become aware of a potential safety issue identified from two recent pharmacoepidemiological studies conducted in Danish data sources, which showed cumulative dose-dependent association between hydrochlorothiazide and Non-Melanoma Skin Cancer (NMSC).
Please download the circular for more information.
The Authority wishes to notify healthcare professionals of reinforcement of safety information about the serios but rare disabling and potentially permanebt side effects associated with fluoroquinolone and quinolone antibiotics.
Please download the circular for more information.
In pursuit of promoting high ethical standards, the Authority has formulated a Code of Ethics for its employees and members of the Authority .The Authority believes that high ethical...
Southern African Development Community (SADC), as a region has harmonized medicines registration guidelines in the common technical document (CTD) format that were approved in January 2015. Nevertheless, the harmonization...
In line with the WHO guidelines on variations and other SRA guidelines, the EVR Division is updating the MCAZ Guidelines for submitting applications for Variations to Registered Medicines. The update...
Background The Medicines Control Authority of Zimbabwe (MCAZ) Regional Centre of Regulatory Excellence (ReCORE) in partnership with the European and Developing Countries Clinical Trials Partnership (EDCTP) is offering...
The Quality Policy of the Medicines Control Authority of Zimbabwe (MCAZ) is to ensure the provision of accurate and timeous services, continuously meet requirements of our customers and guarantee patient...
In this issue: MCAZ turns 20 years Basics of reporting Side Effects of medicines Electronic Adverse Drug Reaction Reporting For more information Please click here to download the Newsletter...
Increased Reporting from the Targeted Spontaneous Reporting (TSR) Programme Click here to download Drug Information Bulletin
Download Complementary medicines applications extension - press statement
The aims of the PV policy handbook are to firstly provide a framework for a national pharmacovigilance system in Zimbabwe. Secondly, to define the pharmacovigilance activities undertaken by the Pharmacovigilance...
The Medicines Control Authority of Zimbabwe (MCAZ) as a responsible corporate citizen runs a Scholarship Fund as part of its corporate social responsibility programmes. Click here to download the...
The approved Guidelines for Advertising and Promotion of Medicines are now available. Download the Guidelines for Advertising and Promotion of Medicines